Unlocking the code: The role of molecular and genetic profiling in revolutionizing glioblastoma treatment
Moustafa A Mansour1, Ahmed M Kamer-Eldawla2, Reem W Malaeb3
1Department of Neurosurgery, Nasser Institute for Research and Treatment, Cairo, Egypt; Department of Neurology and Neurosurgery, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Abstract:
Glioblastoma (GBM) is the most aggressive primary brain cancer, characterized by profound molecular and cellular heterogeneity, which contributes to its resistance to conventional therapies and poor prognosis. Despite multimodal treatments including surgical resection, radiation, and chemotherapy, median survival remains approximately 15 months. Recent advances in molecular and genetic profiling have elucidated key genetic alterations and molecular subtypes of GBM, such as EGFR amplification, PTEN and ATRX loss, and TP53 alterations, which have significant prognostic and therapeutic implications. These discoveries have spurred the development of targeted therapies aimed at disrupting aberrant signaling pathways like RTK/RAS/PI3K and TP53. However, treatment resistance remains a formidable challenge, driven by tumor heterogeneity, the complex tumor microenvironment (TME), and intrinsic adaptive mechanisms. Emerging therapeutic approaches aim to address these challenges, including the use of immunotherapies such as immune checkpoint inhibitors and CAR T-cell therapies, which target specific tumor antigens but face hurdles due to the immunosuppressive TME. Additionally, novel strategies like biopolymer-based interstitial therapies, focused ultrasound for blood-brain barrier disruption, and nanoparticle-based drug delivery systems show promise in enhancing the efficacy and precision of GBM treatments. This review explores the evolving landscape of GBM therapy, emphasizing the importance of personalized medicine through molecular profiling, the potential of combination therapies, and the need for innovative approaches to overcome therapeutic resistance. Continued research into GBM's biology and treatment modalities offers hope for improving patient outcomes.
Insights
Glioblastoma (GBM) is an aggressive brain cancer with poor survival. New therapies target its molecular subtypes and tumor microenvironment, offering hope for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Glioblastoma (GBM) is the most aggressive primary brain cancer, with median survival around 15 months despite multimodal treatments.
- Tumor heterogeneity and the complex tumor microenvironment (TME) contribute to treatment resistance and poor prognosis.
- Advances in molecular profiling reveal key genetic alterations and subtypes (e.g., EGFR amplification, TP53 alterations) with prognostic and therapeutic implications.
Purpose of the Study:
- To review the evolving landscape of Glioblastoma (GBM) therapy.
- To highlight the importance of personalized medicine through molecular profiling.
- To discuss emerging therapeutic strategies and the need for innovative approaches to overcome treatment resistance.
Main Methods:
- Review of recent advances in molecular and genetic profiling of GBM.
- Analysis of targeted therapies disrupting aberrant signaling pathways (e.g., RTK/RAS/PI3K, TP53).
- Exploration of novel therapeutic approaches including immunotherapies, biopolymer-based interstitial therapies, focused ultrasound, and nanoparticle drug delivery.
Main Results:
- Molecular profiling has identified key GBM subtypes and targets for therapy.
- Targeted therapies show promise but face challenges due to resistance mechanisms.
- Emerging strategies like immunotherapy and advanced drug delivery systems aim to enhance treatment efficacy.
- Combination therapies and personalized medicine approaches are crucial for improving outcomes.
Conclusions:
- Overcoming therapeutic resistance in GBM requires innovative strategies addressing tumor heterogeneity and the TME.
- Personalized medicine based on molecular profiling is essential for tailoring GBM treatments.
- Continued research into GBM biology and novel treatment modalities offers hope for improving patient survival and outcomes.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Related Concept Videos
02:18Cancer
02:23Abnormal Proliferation
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...